Dexamethasone Dyspnea Study

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

August 31, 2020

Study Completion Date

January 26, 2021

Conditions
Advanced CancersHematologic DisorderSolid Tumors
Interventions
DRUG

Dexamethasone

"Group 1 Blinded Phase: 8 mg (2 capsules of 4 mg) given orally twice a day for 4 days, then 4 mg given orally twice a day for 3 days.~Open Label Phase Groups 1 and 2: 4 mg by mouth twice a day for 7 days."

DRUG

Placebo

Group 2 Blinded Phase: Two capsules by mouth twice a day for 4 days, followed by one capsule twice a day for 3 days.

BEHAVIORAL

Questionnaires

Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires.

DEVICE

Spirometer

Patient to blow into spirometry machine 1 time a day to test lung function.

OTHER

Phone Calls

Patient called by phone 1 time each day to ask about level of shortness of breath and to remind patient to take capsules. These calls should last about 5 minutes.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT01670097 - Dexamethasone Dyspnea Study | Biotech Hunter | Biotech Hunter